MINIHEP 25,000 IU/ml price in UAE

Overview

Welcome to Dwaey, specifically on MINIHEP 25,000 IU/ml Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Heparin sodium.
MINIHEP 25,000 IU/ml is available in the market in concentration 25,000 IU/ml and in the form of Injection/Solution for.

LEO PHARMACEUTICAL CO. is the producer of MINIHEP 25,000 IU/ml and it is imported from DENMARK, The most popular alternatives of MINIHEP 25,000 IU/ml are listed downward .

Mode Of Action

Heparin increases the inhibitory action of antithrombin III (AT III) on clotting factors XIIa, XIa, IXa, Xa and thrombin. This inhibits the conversion of prothrombin to thrombin and fibrinogen to fibrin. It also inhibits platelet function. It may reduce the activity of ATIII at very high doses.

Indication

Atrial fibrillation
Acute coronary syndrome
Unstable angina
Pulmonary embolism
Thromboembolism
Deep-vein thrombosis
Cardiopulmonary bypass
Hemofiltration
Peripheral arterial embolism

Precaution

Monitor platelet counts. Discontinue treatment if thrombocytopenia occurs. Hypersensitivity, elderly, pregnancy. Lactation: Not excreted in breast milk; compatible

Side Effects

>10% Heparin-induced thrombocytopenia
possibly delayed (10-30% ) Frequency Not Defined Mild pain
Hematoma
Hemorrhage
Local irritation
Erythema
Injection site ulcer (after deep SC injection)
Increased liver aminotransferase
Anaphylaxis
Immune hypersensitivity reaction
Osteoporosis (long-term
high-dose use) Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.

Contra indication

Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.